Kura Oncology Inc (NASDAQ:KURA) – Equities researchers at Oppenheimer cut their FY2022 earnings per share (EPS) estimates for shares of Kura Oncology in a report released on Monday. Oppenheimer analyst L. Cann now anticipates that the company will post earnings of $15.22 per share for the year, down from their previous forecast of $15.89. Oppenheimer currently has a “Buy” rating and a $18.00 price target on the stock.
Several other analysts have also weighed in on KURA. ValuEngine lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Cann restated a “buy” rating and set a $17.50 price target on shares of Kura Oncology in a report on Monday, December 11th. Wedbush assumed coverage on Kura Oncology in a report on Wednesday, December 20th. They set an “outperform” rating and a $19.00 price target on the stock. Finally, Zacks Investment Research downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. One analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $21.67.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Monday, March 12th. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.01).
A number of institutional investors have recently made changes to their positions in KURA. Teachers Advisors LLC bought a new position in Kura Oncology in the 2nd quarter valued at $256,000. TIAA CREF Investment Management LLC bought a new position in Kura Oncology in the 2nd quarter valued at $385,000. Nationwide Fund Advisors grew its position in Kura Oncology by 66.2% in the 2nd quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock valued at $240,000 after acquiring an additional 10,258 shares during the last quarter. New York State Common Retirement Fund bought a new position in Kura Oncology in the 2nd quarter valued at $142,000. Finally, Northern Trust Corp grew its position in Kura Oncology by 939.3% in the 2nd quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock valued at $1,372,000 after acquiring an additional 133,293 shares during the last quarter. 64.65% of the stock is currently owned by institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.